Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied…
Glen Rock, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased…
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health…
-The distinction recognizes faculty who have demonstrated success in translating research into a commercial setting-BOSTON and ATHENS, Ga., March 28,…
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023…
Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March…
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue…
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) --…
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living…
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset…